Brother Enterprises (SZ:002562) Xin Lang Cai Jing·2025-09-21 08:24Core Viewpoint - The company announced that its wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the iodine-pamidronate injection registration certificate, indicating a significant advancement in its product portfolio [1] Group 1: Product Approval - The iodine-pamidronate injection is primarily used for various imaging procedures, including cardiovascular, peripheral artery, venous, coronary, cerebral, urinary tract, spinal, and joint imaging, as well as CT enhancement [1] - The product is characterized by low viscosity and good safety profile, making it a favorable option in the medical imaging market [1] Group 2: Market Inclusion - The iodine-pamidronate injection has been included in the National Medical Insurance Class A directory, which enhances its market accessibility and potential sales [1] - It has also been incorporated into the seventh batch of the National Drug Centralized Procurement directory, indicating a strategic move to streamline procurement processes and potentially reduce costs [1]